RSV and non-RSV illness hospitalization in RSV immunoprophylaxis recipients: A systematic literature review

•Non-respiratory syncytial virus disease hospitalization with immunoprophylaxis use.•No increase in hospitalizations in 5 randomized controlled trials.•Mixed results for hospitalizations in non-randomized studies.•Reason may be differences in clinical characteristics of recipients and controls. Resp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical virology 2020-08, Vol.129, p.104339-104339, Article 104339
Hauptverfasser: Bloomfield, Adam, DeVincenzo, John P., Ambrose, Christopher S., Krilov, Leonard R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Non-respiratory syncytial virus disease hospitalization with immunoprophylaxis use.•No increase in hospitalizations in 5 randomized controlled trials.•Mixed results for hospitalizations in non-randomized studies.•Reason may be differences in clinical characteristics of recipients and controls. Respiratory syncytial virus (RSV) immunoprophylaxis (IP) has been shown to reduce RSV hospitalization rates in high-risk infants; however, it is unclear whether RSV IP is associated with increased risk of non-RSV disease, particularly non-RSV hospitalizations. We conducted a systematic literature review to understand the occurrences of non-RSV disease and/or non-RSV hospitalizations in published studies of RSV IP. Cochrane, Embase, and PubMed databases were searched and reviewed to summarize data regarding the incidence of RSV and non-RSV respiratory disease among RSV IP recipients and controls in randomized and non-randomized studies. Independent investigators screened and selected studies for inclusion. Risk-of-bias assessment was conducted to assess strength/validity of the data using the Jadad scoring system and Downs and Black quality assessment tool, where appropriate. Twenty studies were included for review (5 randomized controlled trials [RCTs]; 15 non-randomized studies). RCTs of RSV IP demonstrated reductions in RSV hospitalizations and all-cause hospitalizations, with no increase in hospitalizations for non-RSV disease. Non-randomized studies also demonstrated reduced RSV hospitalizations in RSV IP recipients but had mixed results in assessments of hospitalizations for non-RSV disease. When RSV IP recipients and controls were more similar in disease severity risk, results of non-randomized studies aligned more closely with RCTs. Observations of increased non-RSV hospitalization rates among RSV IP recipients in some non-randomized studies could be primarily explained by differences in the clinical characteristics between RSV IP recipients and controls.
ISSN:1386-6532
1873-5967
DOI:10.1016/j.jcv.2020.104339